
Novo Nordisk's aspirations to more than double its obesity business by 2025 is way off the mark, according to major US bank J.P. Morgan.
The US analysts, led by Richard Vosser, are confident Novo Nordisk will turn the obesity drug Wegovy into a blockbuster – that is, a drug selling for more than USD 1bn – already next year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app